Bayer Pharma Media Days 2026 highlighted how experts are rethinking cardiovascular diseases, recognizing that heart health often begins in other organs. They provided insights into new imaging tracers, therapies, and prevention tactics.
In a hurry? Here are the key takeaways:
- Heart failure remains underdiagnosed and undertreatedBut emerging gene therapies and disease-modifying approaches—particularly for conditions like ATTR-CM—may significantly improve outcomes.
- Secondary stroke prevention is entering a new eraWith factor XIa inhibitors offering the potential to reduce clotting risk without increasing bleeding complications.
- Molecular imaging is transforming early detectionWith new PET and SPECT tracers enabling earlier diagnosis of systemic diseases like amyloidosis, potentially years before clinical symptoms appear.
March 31–April 1, Bayer Pharma Media Days—Cardiovascular disease can no longer be approached as an isolated cardiac issue. Instead, experts emphasized its systemic nature—spanning kidneys, brain, and even bone marrow—while highlighting innovations that may redefine prevention, diagnosis, and treatment.
This shift is particularly urgent. According to the American Heart Association’s 2026 statistics, heart disease and stroke still account for more than a quarter of all deaths in the United States, despite modest recent declines. Globally, the burden remains immense, with heart failure alone affecting over 64 million people.
Across sessions, Bayer and external experts presented a pipeline that reflects this broader understanding: gene therapies for heart failure, novel anticoagulants for stroke prevention, and molecular imaging tracers capable of detecting disease years before symptoms emerge. Discussions also underscored persistent gaps, especially underdiagnosis, delayed intervention, and inequities in care, notably among women with conditions such as transthyretin amyloid cardiomyopathy (ATTR-CM).
“We are moving from reactive cardiology to proactive cardiovascular care, where earlier detection and targeted therapies can fundamentally alter disease trajectories,” as one expert summarized during the sessions.
READ: “Do you have two minutes for your heart?“, an article published by Bayer.
Heart Failure: From Underdiagnosis to Emerging Therapies
Heart failure remains one of the most under-recognized yet deadly cardiovascular conditions, often diagnosed late due to nonspecific symptoms. During the session, Dr. Muthiah Vaduganathan, Cardiologist at Brigham and Women’s Hospital & Harvard Medical School, highlighted that:
“Patients frequently attribute early symptoms—fatigue, breathlessness—to aging or deconditioning, when in reality these reflect progressive cardiac dysfunction.”
This diagnostic delay contributes to poor outcomes. Approximately half of patients die within five years of diagnosis, a prognosis comparable to many cancers. Yet, as Dr. Lucas Hofmeister, Global Medical Affairs, Heart Failure, Bayer Pharmaceuticals, noted,
“Heart failure does not elicit the same urgency in patients and families as cancer does. There is still a degree of therapeutic nihilism that we must overcome.”
Experts emphasized that heart failure is not a single disease but a systemic syndrome. Up to 40% of patients also have chronic kidney disease, reinforcing the need for integrated care models. This aligns with findings published in Circulation, which stress the interconnected nature of cardiovascular and metabolic disorders and the importance of early, multi-organ intervention.
On the therapeutic front, Bayer is advancing a single-dose investigational gene therapy targeting heart failure with reduced ejection fraction (HFrEF). This approach aims to address underlying molecular drivers rather than simply managing symptoms.
“We are entering an era where disease modification, not just symptom control, is within reach,” Hofmeister said.
Additionally, therapies targeting ATTR-CM—a frequently underdiagnosed cause of heart failure—are gaining traction. By stabilizing the transthyretin (TTR) protein, these treatments address the root cause of amyloid deposition in the heart. Notably, awareness efforts are challenging the long-held misconception that ATTR-CM primarily affects men. As highlighted during the sessions, women are often diagnosed later due to a misconception that cardiovascular events mainly affect men, underscoring the need for heightened clinical vigilance.
Secondary Stroke Prevention: Closing the Residual Risk Gap
Stroke prevention remains a critical challenge, particularly in patients who have already experienced an ischemic event. Despite current therapies, approximately one in five patients will suffer a recurrent stroke within five years. During the roundtable discussion, Dr. Christoph Koenen emphasized the scale of the issue:
“With around 12 million strokes occurring globally each year, the residual risk after a first event is simply too high. We need fundamentally new approaches.”
A key innovation under investigation is factor XIa inhibition. Unlike traditional anticoagulants, which can increase bleeding risk, this strategy aims to “uncouple thrombosis from hemostasis,” as Dr. Stefan Heitmeier explained. By selectively targeting pathological clot formation while preserving normal clotting, these agents may offer improved benefit-risk profiles.
This approach is supported by growing evidence in cardiovascular research suggesting that safer anticoagulation could significantly reduce recurrent events without compromising patient safety. As highlighted in prior studies published in the Journal of the American College of Cardiology, balancing efficacy and bleeding risk remains one of the most pressing challenges in thrombosis management.
Associate Professor Dr. Melinda B. Roaldsen brought a patient-centered perspective to the discussion, having personally survived a major stroke, noting:
“Living with the fear of a second stroke is often as debilitating as the first event itself.”
She stressed the importance of combining pharmacological innovation with patient education and long-term monitoring.
The panel also linked stroke prevention to broader cardiovascular management, particularly atrial fibrillation (AFib), which affects more than 60 million people worldwide. Bayer’s investigation into GIRK4 inhibitors represents another novel avenue, targeting the electrical activity of heart cells to reduce arrhythmia-related stroke risk.
Molecular Imaging: A New Frontier in Early Detection
Perhaps the most forward-looking discussions centered on molecular imaging, particularly the development of two novel tracers designed to detect amyloid deposition with high sensitivity and specificity.
In an interview, Dr. Gesine Knobloch described these tracers as “a critical step toward identifying disease before irreversible organ damage occurs.” One is a PET tracer that has already received FDA Breakthrough Therapy designation for cardiac amyloidosis and holds orphan drug status in both the U.S. and EU, with Phase III dosing completed. The second, a SPECT tracer currently in Phase I, could broaden access to diagnostic imaging due to its wider availability.
These innovations are particularly relevant for conditions like ATTR-CM, where diagnosis is often delayed by years. As discussed during the imaging session, symptoms can begin up to a decade before detection, and historical diagnostic timelines have stretched to four years.
“By the time patients are diagnosed, significant cardiac damage has often already occurred,” Knobloch noted.
Molecular imaging could fundamentally change this trajectory. By enabling earlier and more accurate detection, clinicians may intervene sooner with disease-modifying therapies. This aligns with broader trends in cardiovascular medicine toward precision diagnostics and personalized treatment pathways.
Importantly, these tracers are designed as “pan-amyloid agents,” meaning they can detect amyloid deposits not only in the heart but across multiple organ systems. This reflects the growing recognition of amyloidosis as a systemic disease.
Knobloch emphasized the broader vision:
“Imaging is no longer just about confirming a diagnosis. It is becoming a tool for risk stratification, treatment selection, and even monitoring therapeutic response.”
